Clinical Trial

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

Study acronym: RESOLVE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
Protocol Amendment History 1 change
notable Trial sites expanded: 1 -> 5 locations 2026-07-21
Trial Details
NCT Number NCT07633470
Lead Sponsor Alpha Cognition, Inc
Conditions Alzheimer Disease
Enrollment 150 participants
Start Date 2026-05-20
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-20